MedTrace Logo

Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients

NCT04497389 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2023-12-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to explore the effectiveness of processed human amniotic fluid as a treatment for COVID-19.

Conditions

  • SARS CoV-2

Interventions

BIOLOGICAL

Human Amniotic Fluid

Patients will receive 10ml intravenous hAF each day for 5 consecutive days.

Sponsors & Collaborators

Principal Investigators

  • Craig Selzman, MD · University of Utah

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-28
Primary Completion
2022-08-02
Completion
2023-02-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04497389 on ClinicalTrials.gov